Assembly Biosciences Earnings Call Transcripts
Fiscal Year 2025
-
Phase I-B studies of ABI-1179 and ABI-5366 in recurrent genital herpes showed impressive efficacy, with weekly dosing regimens achieving up to 98% reduction in HSV-2 shedding and strong safety profiles. Both candidates are advancing toward phase II, with further optimization and regulatory discussions planned.
-
The conference highlighted strong interim results for two potent, long-acting herpes virus therapies, with over 90% reduction in viral shedding and lesions, and detailed plans for upcoming data releases and phase 2 trials. The company is also advancing oral hepatitis delta and HBV programs, supported by a robust financial position and partnership with Gilead.
-
Four major clinical catalysts are expected in the next six months, including key data from HBV, hepatitis delta, and genital herpes programs. Large, de-risking trials are underway, with efficacy and convenience as top priorities for advancing assets. Collaboration with Gilead and a strong cash runway support ongoing development.